Showing results (201-210 of 4,238) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|February 9, 2022
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapyRyan C Augustin, Robert D Leone, Aung Naing, et al.Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.Journal for Immunotherapy of Cancer|February 1, 2022
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancerPashtoon Murtaza Kasi, Griffin Budde, Michael Krainock, et al.Journal for Immunotherapy of Cancer|March 15, 2022
Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancerYumeng Wang, Congwen Wang, Junjun Qiu, et al.Journal for Immunotherapy of Cancer|March 15, 2022
Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axisTianyu Tang, Xing Huang, Gang Zhang, et al.Journal for Immunotherapy of Cancer|March 15, 2022
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I studyAung Naing, John D Powderly, John J Nemunaitis, et al.Journal for Immunotherapy of Cancer|March 26, 2022
Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapyXin Liu, Yixiang Xu, Wei Xiong, et al.Journal for Immunotherapy of Cancer|March 26, 2022
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinomaJun Liu, Yang Yang, Zhichao Liu, et al.Journal for Immunotherapy of Cancer|March 17, 2022
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 studyHaiping Jiang, Xiongfei Yu, Ning Li, et al.Journal for Immunotherapy of Cancer|March 17, 2022
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathwayYe Shen, Jason S Eng, Flordeliza Fajardo, et al.Pageof 424